Research Analysts Set Expectations for CorMedix Q3 Earnings

CorMedix Inc (NASDAQ:CRMD) – Investment analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for CorMedix in a note issued to investors on Friday, August 14th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.08). The consensus estimate for CorMedix’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for CorMedix’s Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.54 EPS.

CRMD has been the subject of several other research reports. Royal Bank Of Canada raised their price target on shares of CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday. Needham & Company LLC lifted their target price on shares of CorMedix from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of CorMedix in a research report on Monday, April 27th. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a report on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

CorMedix Trading Up 1.7%

NASDAQ CRMD opened at $7.67 on Tuesday. The firm has a market capitalization of $597.80 million, a PE ratio of 3.58 and a beta of 1.50. The business’s 50-day moving average price is $8.12 and its two-hundred day moving average price is $7.64. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. CorMedix has a 12 month low of $6.13 and a 12 month high of $14.96.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. The firm had revenue of $101.93 million during the quarter, compared to analysts’ expectations of $96.04 million. CorMedix had a net margin of 40.49% and a return on equity of 40.52%.

Institutional Investors Weigh In On CorMedix

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC acquired a new position in shares of CorMedix during the second quarter worth approximately $1,909,000. Hayek Kallen Investment Management bought a new position in shares of CorMedix in the second quarter valued at $123,000. Corient Private Wealth LP acquired a new position in shares of CorMedix during the second quarter valued at about $755,000. Bank of America Corp DE acquired a new position in shares of CorMedix during the second quarter valued at about $1,183,000. Finally, Freestone Grove Partners LP acquired a new stake in shares of CorMedix in the 2nd quarter worth about $262,000. Institutional investors own 34.18% of the company’s stock.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.